Sartorius buys Danaher’s life sciences tools businesses for $750 Mn
Category: #business  By Pankaj Singh  Date: 2019-10-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sartorius buys Danaher’s life sciences tools businesses for $750 Mn

Global life sciences tools market is projected to witness substantial growth in the forthcoming years owing to their advancements and usage in the biotechnology sector. The growing prominence of the field and the subsequent rise in competition is further making way for various acquisitions and collaborations in the industry.

Sartorius Group, a renowned German laboratory and pharmaceutical equipment supplier, reportedly announced the acquisition of three life sciences tool businesses from Danaher Life Sciences, a US-based life sciences and diagnostics division of Danaher Corporation. The acquisition would cost Sartorius approximately $750 million, which will be a cash transaction.

These businesses had joint sales revenue of about $140 million last year with double-digit profit margins and a robust growth profile. The businesses together employ approximately 300 people across the globe.

The proposed agreement is predicted to be completed by the first financial quarter of 2020. The proposed transaction would be subject to all the customary closing conditions and complete, successful procurement of the GE Biopharma business by Danaher Corporation.

The three business tools that would be acquired by Sartorius are FortéBio, a label-free biomolecular characterization business, chromatography hardware and microcarriers, and resins SoloHill business.  

Sartorius CEO, Dr. Joachim Kreuzburg stated that the portfolio proposed by Danaher for purchase indicates an excellent strategic fit with the company. Through the FortéBio Octet platform, the company would incorporate a widely accepted as well as differentiated technology for simplifying and advancing drug discovery to the company’s lab division portfolio.

Kreuzburg added that chromatography hardware and resins and the microcarrier businesses widen the company’s robust bioprocessing offering, specifically in the downstream area. Sartorius looks forward to welcoming new teams from Danaher to the company and jointly combine both of their capabilities to further benefit the company’s biopharma and life science consumers.

Danaher stated that it entered into a business agreement with Sartorius as a step to obtain regulatory approval for the acquisition of the GE Biopharma business which is currently pending. In February, Danaher agreed to acquire the GE Life Sciences’ biopharma business for approximately $21.4 billion in cash, in a contract designed to improve the purchaser’s bioprocessing offerings and pay down the debt of the seller.

 

Source credit: https://www.businesswire.com/news/home/20191020005084/en/Sartorius-Signs-Agreement-Acquire-Select-Danaher-Life

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Merck acquires Calporta Therapeutics from COI Pharmaceuticals
Merck acquires Calporta Therapeutics from COI Pharmaceuticals
By Pankaj Singh

Merck will pay up to $576 million for the acquisition   Preclinical TRPML1 has the potential to treat neurodegenerative and lysosomal disorders COI Pharmaceuticals has recently announced that Merck, also called MSD outside Canada and the U...

Personalis unveils new service for cancer whole genome sequencing
Personalis unveils new service for cancer whole genome sequencing
By Pankaj Singh

  The new launch of the services will help the company expand its oncology portfolio Personalis has been able to sequence more than 40,000 MVP samples since 2013. Personalis, Inc., a leading advanced genomics firm for cancer, recently unve...

Celltrion depicts CT-P13 SC efficacy for treating rheumatoid arthritis
Celltrion depicts CT-P13 SC efficacy for treating rheumatoid arthritis
By Pankaj Singh

Celltrion Healthcare, a biopharmaceutical company, recently announced data from a study further investigating efficacy, safety, immunogenicity & pharmacokinetics of CT-P13 SC, over a period of 1-year treatment. The study focuses on the results ac...